Abstract:Background The chemoresistance of prostate cancer (PCa) is invariably associated with the aggressiveness and metastasis of this disease. New emerging evidence indicates that the epithelial-to-mesenchymal transition (EMT) may play pivotal roles in the development of chemoresistance and metastasis. As a hallmark of EMT, E-cadherin is suggested to be a key marker in the development of chemoresistance. However, the molecular mechanisms underlying PCa chemoresistance remain unclear. The current study aimed to explore the association between EMT and chemoresistance in PCa as well as whether changing the expression of E-cadherin would affect PCa chemoresistance. Methods Parental PC3 and DU145 cells and their chemoresistant PC3-TxR and DU145-TxR cells were analyzed. PC3-TxR and DU145-TxR cells were transfected with E-cadherin-expressing lentivirus to overexpress E-cadherin; PC3 and DU145 cells were transfected with small interfering RNA to silence E-cadherin. Changes of EMT phenotype-related markers and signaling pathways were assessed by Western blotting and quantitative real-time polymerase chain reaction. Tumor cell migration, invasion, and colony formation were then evaluated by wound healing, transwell, and colony formation assays, respectively. The drug sensitivity was evaluated using MTS assay. Results Chemoresistant PC3-TxR and DU145-TxR cells exhibited an invasive and metastatic phenotype that associated with EMT, including the down-regulation of E-cadherin and up-regulation of Vimentin, Snail, and N-cadherin, comparing with that of parental PC3 and DU145 cells. When E-cadherin was overexpressed in PC3-TxR and DU145-TxR cells, the expression of Vimentin and Claudin-1 was down-regulated, and tumor cell migration and invasion were inhibited. In particular, the sensitivity to paclitaxel was reactivated in E-cadherin-overexpressing PC3-TxR and DU145-TxR cells. When E-cadherin expression was silenced in parental PC3 and DU145 cells, the expression of Vimentin and Snail was up-regulated, and, particularly, the sensitivity to paclitaxel was decreased. Interestingly, Notch-1 expression was up-regulated in PC3-TxR and DU145-TxR cells, whereas the E-cadherin expression was down-regulated in these cells comparing with their parental cells. The use of γ-secretase inhibitor, a Notch signaling pathway inhibitor, significantly increased the sensitivity of chemoresistant cells to paclitaxel. Conclusion The down-regulation of E-cadherin enhances PCa chemoresistance via Notch signaling, and inhibiting the Notch signaling pathway may reverse PCa chemoresistance.

Silencing Notch-1 Induces Apoptosis and Increases the Chemosensitivity of Prostate Cancer Cells to Docetaxel Through Bcl-2 and Bax

Sirna-Mediated Silencing of Notch-1 Enhances Docetaxel Induced Mitotic Arrest and Apoptosis in Prostate Cancer Cells.

Inhibition of Notch Pathway Enhances the Anti-Tumor Effect of Docetaxel in Prostate Cancer Stem-Like Cells

Down‐regulation of Notch‐1 and Jagged‐1 Inhibits Prostate Cancer Cell Growth, Migration and Invasion, and Induces Apoptosis Via Inactivation of Akt, Mtor, and NF‐κB Signaling Pathways

NOTCH1 signaling promotes chemoresistance via regulating ABCC1 expression in prostate cancer stem cells

Reversal of Docetaxel Resistance in Prostate Cancer by Notch Signaling Inhibition

CNTN-1 promotes docetaxel resistance and epithelial-to-mesenchymal transition via the PI3K/Akt signaling pathway in prostate cancer

Anticancer Effect of Docetaxel Induces Apoptosis of Prostate Cancer Via the Cofilin-1 and Paxillin Signaling Pathway.

Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling

Down-regulation of Notch-1 Contributes to Cell Growth Inhibition and Apoptosis in Pancreatic Cancer Cells

Pharmacological Inhibition of the Notch Pathway Enhances the Efficacy of Androgen Deprivation Therapy for Prostate Cancer.

Retracted: Notch‐1 Down‐regulation by Curcumin is Associated with the Inhibition of Cell Growth and the Induction of Apoptosis in Pancreatic Cancer Cells

Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch.

Silencing of LINC01963 enhances the chemosensitivity of prostate cancer cells to docetaxel by targeting the miR-216b-5p/TrkB axis

Inhibition Of Notch1 Increases Paclitaxel Sensitivity To Human Breast Cancer

Notch1 Suppresses Prostate Cancer Cell Invasion Via the Metastasis-Associated 1-Kiss-1 Metastasis-Suppressor Pathway

Silencing of CDC20 Suppresses Metastatic Castration-Resistant Prostate Cancer Growth and Enhances Chemosensitivity to Docetaxel.

Targeted Inhibition of Notch1 Gene Enhances the Killing Effects of Paclitaxel on Triple Negative Breast Cancer Cells.

In vitro modulation the Notch pathway by piperine: A therapeutic strategy for docetaxel‐resistant and non‐resistant prostate cancer

Rnai-Mediated Knockdown Of Notch-1 Leads To Cell Growth Inhibition And Enhanced Chemosensitivity In Human Breast Cancer

Notch-1 Confers Chemoresistance in Lung Adenocarcinoma to Taxanes Through AP-1/microRNA-451 Mediated Regulation of MDR-1